Spyre Therapeutics, Inc. (NASDAQ: SYRE) Stock Competitors & Peer Comparison
See SYRE's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SYRE and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SYRE | $108.65 | -0.25% | 9.4B | -55.28 | -$1.95 | N/A |
| VRTX | $550.44 | -0.29% | 137.1B | 28.39 | $19.03 | N/A |
| REGN | $843.24 | +0.29% | 85.2B | 18.12 | $45.63 | +0.44% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $1,048.66 | +1.53% | 64.6B | 93.69 | $11.08 | N/A |
| MRNA | $152.65 | -12.46% | 52.9B | -16.36 | -$8.15 | N/A |
| RVMDW | $11.80 | -3.99% | 47.1B | -1.66 | -$7.21 | N/A |
| RVMD | $208.77 | -2.74% | 45B | -24.01 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $377.92 | +0.28% | 39.4B | 64.99 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
SYRE vs VRTX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, VRTX has a market cap of 137.1B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while VRTX trades at $550.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas VRTX's P/E ratio is 28.39. In terms of profitability, SYRE's ROE is -0.24%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, SYRE is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
SYRE vs REGN Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, REGN has a market cap of 85.2B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while REGN trades at $843.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas REGN's P/E ratio is 18.12. In terms of profitability, SYRE's ROE is -0.24%, compared to REGN's ROE of +0.14%. Regarding short-term risk, SYRE is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
SYRE vs VRNA Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas VRNA's P/E ratio is -102.80. In terms of profitability, SYRE's ROE is -0.24%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, SYRE is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
SYRE vs ARGX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ARGX has a market cap of 64.6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ARGX trades at $1,048.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ARGX's P/E ratio is 93.69. In terms of profitability, SYRE's ROE is -0.24%, compared to ARGX's ROE of +0.32%. Regarding short-term risk, SYRE is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check ARGX's competition here
Moderna, Inc. (NASDAQ: MRNA)
SYRE vs MRNA Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, MRNA has a market cap of 52.9B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while MRNA trades at $152.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas MRNA's P/E ratio is -16.36. In terms of profitability, SYRE's ROE is -0.24%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, SYRE is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check MRNA's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
SYRE vs RVMDW Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, RVMDW has a market cap of 47.1B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while RVMDW trades at $11.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas RVMDW's P/E ratio is -1.66. In terms of profitability, SYRE's ROE is -0.24%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, SYRE is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
SYRE vs RVMD Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, RVMD has a market cap of 45B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while RVMD trades at $208.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas RVMD's P/E ratio is -24.01. In terms of profitability, SYRE's ROE is -0.24%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, SYRE is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
SYRE vs SGEN Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SYRE's ROE is -0.24%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SYRE is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
SYRE vs ONC Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ONC has a market cap of 39.4B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ONC trades at $377.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ONC's P/E ratio is 64.99. In terms of profitability, SYRE's ROE is -0.24%, compared to ONC's ROE of +0.14%. Regarding short-term risk, SYRE is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
SYRE vs ALNY Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ALNY has a market cap of 30.7B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ALNY trades at $234.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ALNY's P/E ratio is 41.32. In terms of profitability, SYRE's ROE is -0.24%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, SYRE is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check ALNY's competition here
BioNTech SE (NASDAQ: BNTX)
SYRE vs BNTX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, BNTX has a market cap of 27.9B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while BNTX trades at $119.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas BNTX's P/E ratio is -20.07. In terms of profitability, SYRE's ROE is -0.24%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, SYRE is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check BNTX's competition here
Insmed Incorporated (NASDAQ: INSM)
SYRE vs INSM Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, INSM has a market cap of 27.1B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while INSM trades at $126.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas INSM's P/E ratio is -27.37. In terms of profitability, SYRE's ROE is -0.24%, compared to INSM's ROE of -1.11%. Regarding short-term risk, SYRE is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check INSM's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
SYRE vs ROIV Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ROIV has a market cap of 26.6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ROIV trades at $36.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ROIV's P/E ratio is -35.05. In terms of profitability, SYRE's ROE is -0.24%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, SYRE is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check ROIV's competition here
Incyte Corporation (NASDAQ: INCY)
SYRE vs INCY Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, INCY has a market cap of 25.8B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while INCY trades at $129.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas INCY's P/E ratio is 17.10. In terms of profitability, SYRE's ROE is -0.24%, compared to INCY's ROE of +0.30%. Regarding short-term risk, SYRE is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
SYRE vs UTHR Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, UTHR has a market cap of 22.1B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while UTHR trades at $524.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas UTHR's P/E ratio is 18.64. In terms of profitability, SYRE's ROE is -0.24%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, SYRE is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
SYRE vs GMAB Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, GMAB has a market cap of 20.5B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while GMAB trades at $33.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas GMAB's P/E ratio is 25.18. In terms of profitability, SYRE's ROE is -0.24%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, SYRE is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
SYRE vs BGNE Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SYRE's ROE is -0.24%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, SYRE is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
SYRE vs DNA-WT Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SYRE's ROE is -0.24%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, SYRE is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check DNA-WT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
SYRE vs BBIO Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, BBIO has a market cap of 16.2B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while BBIO trades at $82.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas BBIO's P/E ratio is -22.18. In terms of profitability, SYRE's ROE is -0.24%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, SYRE is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check BBIO's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
SYRE vs ASND Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ASND has a market cap of 15.8B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ASND trades at $255.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ASND's P/E ratio is -105.29. In terms of profitability, SYRE's ROE is -0.24%, compared to ASND's ROE of +1.90%. Regarding short-term risk, SYRE is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check ASND's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
SYRE vs JAZZ Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, JAZZ has a market cap of 15.6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while JAZZ trades at $252.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas JAZZ's P/E ratio is 9.27. In terms of profitability, SYRE's ROE is -0.24%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, SYRE is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check JAZZ's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
SYRE vs NBIX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, NBIX has a market cap of 15.4B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while NBIX trades at $153.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas NBIX's P/E ratio is 22.10. In terms of profitability, SYRE's ROE is -0.24%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, SYRE is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
SYRE vs EXEL Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, EXEL has a market cap of 13.5B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while EXEL trades at $54.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas EXEL's P/E ratio is 15.34. In terms of profitability, SYRE's ROE is -0.24%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, SYRE is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check EXEL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
SYRE vs BMRN Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, BMRN has a market cap of 13.1B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while BMRN trades at $67.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas BMRN's P/E ratio is 32.54. In terms of profitability, SYRE's ROE is -0.24%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, SYRE is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check BMRN's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
SYRE vs KRTX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SYRE's ROE is -0.24%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SYRE is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check KRTX's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
SYRE vs HALO Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, HALO has a market cap of 12.6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while HALO trades at $107.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas HALO's P/E ratio is 19.80. In terms of profitability, SYRE's ROE is -0.24%, compared to HALO's ROE of +1.81%. Regarding short-term risk, SYRE is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check HALO's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
SYRE vs ARWR Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ARWR has a market cap of 12.3B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ARWR trades at $86.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ARWR's P/E ratio is -38.88. In terms of profitability, SYRE's ROE is -0.24%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, SYRE is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check ARWR's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
SYRE vs MDGL Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, MDGL has a market cap of 12B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while MDGL trades at $528.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas MDGL's P/E ratio is -40.55. In terms of profitability, SYRE's ROE is -0.24%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, SYRE is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
SYRE vs TECH Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while TECH trades at $72.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas TECH's P/E ratio is 37.26. In terms of profitability, SYRE's ROE is -0.24%, compared to TECH's ROE of +0.09%. Regarding short-term risk, SYRE is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
SYRE vs RNAM Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas RNAM's P/E ratio is -17.39. In terms of profitability, SYRE's ROE is -0.24%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, SYRE is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
SYRE vs AXSM Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, AXSM has a market cap of 10.7B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while AXSM trades at $208.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas AXSM's P/E ratio is -54.32. In terms of profitability, SYRE's ROE is -0.24%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, SYRE is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check AXSM's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
SYRE vs PRAX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, PRAX has a market cap of 10.2B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while PRAX trades at $381.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas PRAX's P/E ratio is -28.20. In terms of profitability, SYRE's ROE is -0.24%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, SYRE is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check PRAX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
SYRE vs KYMR Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, KYMR has a market cap of 10B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while KYMR trades at $123.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas KYMR's P/E ratio is -37.97. In terms of profitability, SYRE's ROE is -0.24%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, SYRE is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check KYMR's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
SYRE vs PTGX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, PTGX has a market cap of 10B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while PTGX trades at $152.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas PTGX's P/E ratio is 150.43. In terms of profitability, SYRE's ROE is -0.24%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, SYRE is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check PTGX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
SYRE vs KRYS Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, KRYS has a market cap of 9.9B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while KRYS trades at $339.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas KRYS's P/E ratio is 42.23. In terms of profitability, SYRE's ROE is -0.24%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, SYRE is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check KRYS's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
SYRE vs SMMT Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, SMMT has a market cap of 9.9B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while SMMT trades at $13.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas SMMT's P/E ratio is -7.77. In terms of profitability, SYRE's ROE is -0.24%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, SYRE is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check SMMT's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
SYRE vs IONS Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, IONS has a market cap of 9.8B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while IONS trades at $60.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas IONS's P/E ratio is -34.16. In terms of profitability, SYRE's ROE is -0.24%, compared to IONS's ROE of -1.11%. Regarding short-term risk, SYRE is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check IONS's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
SYRE vs CYTK Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, CYTK has a market cap of 9.6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while CYTK trades at $77.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas CYTK's P/E ratio is -10.69. In terms of profitability, SYRE's ROE is -0.24%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, SYRE is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check CYTK's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
SYRE vs RXDX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SYRE's ROE is -0.24%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SYRE is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check RXDX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
SYRE vs IMVT Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, IMVT has a market cap of 9.2B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while IMVT trades at $44.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas IMVT's P/E ratio is -15.73. In terms of profitability, SYRE's ROE is -0.24%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, SYRE is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check IMVT's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
SYRE vs NUVL Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas NUVL's P/E ratio is -21.79. In terms of profitability, SYRE's ROE is -0.24%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, SYRE is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
SYRE vs CRNX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while CRNX trades at $84.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas CRNX's P/E ratio is -16.80. In terms of profitability, SYRE's ROE is -0.24%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, SYRE is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check CRNX's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
SYRE vs PCVX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, PCVX has a market cap of 8.9B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while PCVX trades at $63.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas PCVX's P/E ratio is -8.04. In terms of profitability, SYRE's ROE is -0.24%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, SYRE is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check PCVX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
SYRE vs IMGN Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SYRE's ROE is -0.24%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, SYRE is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check IMGN's competition here
Abivax S.A. (NASDAQ: ABVX)
SYRE vs ABVX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ABVX has a market cap of 8.7B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ABVX trades at $118.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ABVX's P/E ratio is -61.95. In terms of profitability, SYRE's ROE is -0.24%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, SYRE is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check ABVX's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
SYRE vs BPMC Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas BPMC's P/E ratio is -51.58. In terms of profitability, SYRE's ROE is -0.24%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, SYRE is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
SYRE vs APGE Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, APGE has a market cap of 8.3B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while APGE trades at $134.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas APGE's P/E ratio is -31.12. In terms of profitability, SYRE's ROE is -0.24%, compared to APGE's ROE of -0.30%. Regarding short-term risk, SYRE is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check APGE's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
SYRE vs IBRX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, IBRX has a market cap of 8.2B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while IBRX trades at $7.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas IBRX's P/E ratio is -8.08. In terms of profitability, SYRE's ROE is -0.24%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, SYRE is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check IBRX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
SYRE vs CERE Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas CERE's P/E ratio is -16.47. In terms of profitability, SYRE's ROE is -0.24%, compared to CERE's ROE of -0.72%. Regarding short-term risk, SYRE is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check CERE's competition here
Alkermes plc (NASDAQ: ALKS)
SYRE vs ALKS Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ALKS has a market cap of 8.1B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ALKS trades at $48.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ALKS's P/E ratio is 50.55. In terms of profitability, SYRE's ROE is -0.24%, compared to ALKS's ROE of +0.04%. Regarding short-term risk, SYRE is less volatile compared to ALKS. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check ALKS's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
SYRE vs TGTX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, TGTX has a market cap of 7.7B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while TGTX trades at $55.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas TGTX's P/E ratio is 18.32. In terms of profitability, SYRE's ROE is -0.24%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, SYRE is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check TGTX's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
SYRE vs RYTM Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, RYTM has a market cap of 7.5B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while RYTM trades at $111.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas RYTM's P/E ratio is -35.02. In terms of profitability, SYRE's ROE is -0.24%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, SYRE is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check RYTM's competition here
Metsera, Inc. (NASDAQ: MTSR)
SYRE vs MTSR Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas MTSR's P/E ratio is -23.58. In terms of profitability, SYRE's ROE is -0.24%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, SYRE is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check MTSR's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
SYRE vs CAI Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, CAI has a market cap of 6.9B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while CAI trades at $26.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas CAI's P/E ratio is 69.06. In terms of profitability, SYRE's ROE is -0.24%, compared to CAI's ROE of +0.19%. Regarding short-term risk, SYRE is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check CAI's competition here
CG Oncology Inc. (NASDAQ: CGON)
SYRE vs CGON Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, CGON has a market cap of 6.8B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while CGON trades at $78.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas CGON's P/E ratio is -28.85. In terms of profitability, SYRE's ROE is -0.24%, compared to CGON's ROE of -0.25%. Regarding short-term risk, SYRE is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
SYRE vs MRUS Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas MRUS's P/E ratio is -17.05. In terms of profitability, SYRE's ROE is -0.24%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, SYRE is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
SYRE vs ACLX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ACLX's P/E ratio is -28.27. In terms of profitability, SYRE's ROE is -0.24%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, SYRE is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check ACLX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
SYRE vs SRRK Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, SRRK has a market cap of 6.6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while SRRK trades at $55.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas SRRK's P/E ratio is -16.01. In terms of profitability, SYRE's ROE is -0.24%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, SYRE is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check SRRK's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
SYRE vs RETA Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas RETA's P/E ratio is -66.29. In terms of profitability, SYRE's ROE is -0.24%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SYRE is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
SYRE vs BLTE Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while BLTE trades at $162.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas BLTE's P/E ratio is -86.60. In terms of profitability, SYRE's ROE is -0.24%, compared to BLTE's ROE of -0.21%. Regarding short-term risk, SYRE is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check BLTE's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
SYRE vs ORKA Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ORKA has a market cap of 6.3B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ORKA trades at $108.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ORKA's P/E ratio is -54.05. In terms of profitability, SYRE's ROE is -0.24%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, SYRE is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check ORKA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
SYRE vs CNTA Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas CNTA's P/E ratio is -22.63. In terms of profitability, SYRE's ROE is -0.24%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, SYRE is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check CNTA's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
SYRE vs PTCT Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, PTCT has a market cap of 6.1B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while PTCT trades at $70.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas PTCT's P/E ratio is -31.62. In terms of profitability, SYRE's ROE is -0.24%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, SYRE is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check PTCT's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
SYRE vs DNTH Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, DNTH has a market cap of 6.1B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while DNTH trades at $111.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas DNTH's P/E ratio is -26.39. In terms of profitability, SYRE's ROE is -0.24%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, SYRE is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check DNTH's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
SYRE vs COGT Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, COGT has a market cap of 6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while COGT trades at $36.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas COGT's P/E ratio is -16.73. In terms of profitability, SYRE's ROE is -0.24%, compared to COGT's ROE of -0.73%. Regarding short-term risk, SYRE is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check COGT's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
SYRE vs DFTX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, DFTX has a market cap of 6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while DFTX trades at $45.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas DFTX's P/E ratio is N/A. In terms of profitability, SYRE's ROE is -0.24%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, SYRE is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check DFTX's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
SYRE vs TVTX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, TVTX has a market cap of 6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while TVTX trades at $65.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas TVTX's P/E ratio is -143.24. In terms of profitability, SYRE's ROE is -0.24%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, SYRE is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check TVTX's competition here
Erasca, Inc. (NASDAQ: ERAS)
SYRE vs ERAS Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ERAS has a market cap of 5.9B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ERAS trades at $17.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ERAS's P/E ratio is -18.37. In terms of profitability, SYRE's ROE is -0.24%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, SYRE is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check ERAS's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
SYRE vs MIRM Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, MIRM has a market cap of 5.9B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while MIRM trades at $96.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas MIRM's P/E ratio is -6.67. In terms of profitability, SYRE's ROE is -0.24%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, SYRE is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check MIRM's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
SYRE vs XENE Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, XENE has a market cap of 5.8B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while XENE trades at $60.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas XENE's P/E ratio is -12.71. In terms of profitability, SYRE's ROE is -0.24%, compared to XENE's ROE of -0.44%. Regarding short-term risk, SYRE is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check XENE's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
SYRE vs LGND Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while LGND trades at $287.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas LGND's P/E ratio is 31.55. In terms of profitability, SYRE's ROE is -0.24%, compared to LGND's ROE of +0.20%. Regarding short-term risk, SYRE is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check LGND's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
SYRE vs CDTX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas CDTX's P/E ratio is -19.77. In terms of profitability, SYRE's ROE is -0.24%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, SYRE is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check CDTX's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
SYRE vs CRSP Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while CRSP trades at $61.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas CRSP's P/E ratio is -12.21. In terms of profitability, SYRE's ROE is -0.24%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, SYRE is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check CRSP's competition here
Abcam plc (NASDAQ: ABCM)
SYRE vs ABCM Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SYRE's ROE is -0.24%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SYRE is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
SYRE vs ISEE Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SYRE's ROE is -0.24%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SYRE is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check ISEE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
SYRE vs APLS Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas APLS's P/E ratio is 38.35. In terms of profitability, SYRE's ROE is -0.24%, compared to APLS's ROE of +0.40%. Regarding short-term risk, SYRE is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check APLS's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
SYRE vs ACAD Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ACAD has a market cap of 5B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ACAD trades at $29.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ACAD's P/E ratio is 13.08. In terms of profitability, SYRE's ROE is -0.24%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, SYRE is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check ACAD's competition here
Dyne Therapeutics, Inc. (NASDAQ: DYN)
SYRE vs DYN Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, DYN has a market cap of 4.9B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while DYN trades at $26.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas DYN's P/E ratio is -8.07. In terms of profitability, SYRE's ROE is -0.24%, compared to DYN's ROE of -0.64%. Regarding short-term risk, SYRE is less volatile compared to DYN. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check DYN's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
SYRE vs TERN Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas TERN's P/E ratio is -51.41. In terms of profitability, SYRE's ROE is -0.24%, compared to TERN's ROE of -0.20%. Regarding short-term risk, SYRE is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check TERN's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
SYRE vs EWTX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, EWTX has a market cap of 4.7B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while EWTX trades at $43.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas EWTX's P/E ratio is -23.40. In terms of profitability, SYRE's ROE is -0.24%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, SYRE is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check EWTX's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
SYRE vs PBLS Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, PBLS has a market cap of 4.6B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while PBLS trades at $39.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas PBLS's P/E ratio is -44.98. In terms of profitability, SYRE's ROE is -0.24%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, SYRE is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check PBLS's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
SYRE vs FOLD Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas FOLD's P/E ratio is -161.00. In terms of profitability, SYRE's ROE is -0.24%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, SYRE is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
SYRE vs AKRO Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas AKRO's P/E ratio is -14.57. In terms of profitability, SYRE's ROE is -0.24%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, SYRE is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
SYRE vs ALPN Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SYRE's ROE is -0.24%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, SYRE is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check ALPN's competition here
Celcuity Inc. (NASDAQ: CELC)
SYRE vs CELC Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, CELC has a market cap of 4.4B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while CELC trades at $93.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas CELC's P/E ratio is -21.06. In terms of profitability, SYRE's ROE is -0.24%, compared to CELC's ROE of -3.51%. Regarding short-term risk, SYRE is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check CELC's competition here
Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX)
SYRE vs AMLX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, AMLX has a market cap of 4.4B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while AMLX trades at $40.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas AMLX's P/E ratio is -26.44. In terms of profitability, SYRE's ROE is -0.24%, compared to AMLX's ROE of -0.53%. Regarding short-term risk, SYRE is less volatile compared to AMLX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check AMLX's competition here
Veradermics, Incorporated (NYSE: MANE)
SYRE vs MANE Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, MANE has a market cap of 4.4B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while MANE trades at $106.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas MANE's P/E ratio is -33.47. In terms of profitability, SYRE's ROE is -0.24%, compared to MANE's ROE of -0.29%. Regarding short-term risk, SYRE is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check MANE's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
SYRE vs RLAY Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, RLAY has a market cap of 4.3B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while RLAY trades at $19.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas RLAY's P/E ratio is -12.55. In terms of profitability, SYRE's ROE is -0.24%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, SYRE is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check RLAY's competition here
Opthea Limited (NASDAQ: OPT)
SYRE vs OPT Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas OPT's P/E ratio is -1.52. In terms of profitability, SYRE's ROE is -0.24%, compared to OPT's ROE of +1.18%. Regarding short-term risk, SYRE is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
SYRE vs PRTC Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas PRTC's P/E ratio is -3.78. In terms of profitability, SYRE's ROE is -0.24%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, SYRE is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check PRTC's competition here
Enliven Therapeutics, Inc. (NASDAQ: ELVN)
SYRE vs ELVN Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ELVN has a market cap of 4.2B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ELVN trades at $58.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ELVN's P/E ratio is -35.28. In terms of profitability, SYRE's ROE is -0.24%, compared to ELVN's ROE of -0.19%. Regarding short-term risk, SYRE is less volatile compared to ELVN. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check ELVN's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
SYRE vs TLX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, TLX has a market cap of 4.2B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while TLX trades at $11.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas TLX's P/E ratio is -675.00. In terms of profitability, SYRE's ROE is -0.24%, compared to TLX's ROE of -0.02%. Regarding short-term risk, SYRE is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check TLX's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
SYRE vs MRTX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SYRE's ROE is -0.24%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SYRE is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check MRTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
SYRE vs ADPT Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, ADPT has a market cap of 4.1B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while ADPT trades at $25.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas ADPT's P/E ratio is -62.05. In terms of profitability, SYRE's ROE is -0.24%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, SYRE is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check ADPT's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
SYRE vs IOVA Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, IOVA has a market cap of 4B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while IOVA trades at $8.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas IOVA's P/E ratio is -9.46. In terms of profitability, SYRE's ROE is -0.24%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, SYRE is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check IOVA's competition here
Viking Therapeutics, Inc. (NASDAQ: VKTX)
SYRE vs VKTX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, VKTX has a market cap of 4B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while VKTX trades at $34.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas VKTX's P/E ratio is -8.30. In terms of profitability, SYRE's ROE is -0.24%, compared to VKTX's ROE of -0.95%. Regarding short-term risk, SYRE is more volatile compared to VKTX. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check VKTX's competition here
Denali Therapeutics Inc. (NASDAQ: DNLI)
SYRE vs DNLI Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, DNLI has a market cap of 4B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while DNLI trades at $24.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas DNLI's P/E ratio is -8.66. In terms of profitability, SYRE's ROE is -0.24%, compared to DNLI's ROE of -0.55%. Regarding short-term risk, SYRE is more volatile compared to DNLI. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check DNLI's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
SYRE vs LEGN Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, LEGN has a market cap of 3.9B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while LEGN trades at $22.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas LEGN's P/E ratio is -31.26. In terms of profitability, SYRE's ROE is -0.24%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, SYRE is less volatile compared to LEGN. This indicates lower risk in terms of short-term price fluctuations for SYRE.Check LEGN's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
SYRE vs CPRX Comparison August 2026
Spyre Therapeutics, Inc. (NASDAQ: SYRE) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SYRE stands at 9.4B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, SYRE is priced at $108.65 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SYRE currently has a P/E ratio of -55.28, whereas CPRX's P/E ratio is 12.30. In terms of profitability, SYRE's ROE is -0.24%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, SYRE is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for SYRE.Check CPRX's competition here